. Author manuscript; available in PMC: 2013 May 1.

Published in final edited form as: Brain Behav Immun. 2012 Feb 2;26(4):543–551. doi: 10.1016/j.bbi.2012.01.019

Table 4.

ANCOVA Tests of differences in salivary CRP for AHA risk categories based on plasma CRP

	n (%)	M (SE)^a	F	Contrasts
Wave 1			5.93^**	1 = 2, 1 < 3, 1 < 4
1. CRP < 1 mg/L	31 (30)	6.96 (0.24)		2 < 3, 2 < 4, 3 < 4
2. CRP 1 – 3 mg/L	31 (30)	7.41 (0.23)
3. CRP 3 – 10 mg/	26 (25)	8.33 (0.26)
4. CRP > 10 mg/L	17 (16)	9.27 (0.31)

Wave 4			3.27^**	1 = 2, 1 = 3, 1 < 4
1. CRP < 1 mg/L	21 (18)	6.89 (0.31)		2 = 3, 2 < 4, 3 < 4
2. CRP 1 – 3 mg/L	38 (32)	7.14 (0.23)
3. CRP 3 – 10 mg/L	39 (33)	7.53 (0.22)
4. CRP > 10 mg/L	19 (16)	8.56 (0.32)

Wave 7			4.69^**	1 = 2, 1 < 3, 1 < 4
1. CRP < 1 mg/L	29 (31)	6.52 (0.21)		2 = 3, 2 < 4, 3 = 4
2. CRP 1 – 3 mg/L	30 (32)	6.94 (0.19)
3. CRP 3 – 10 mg/L	22 (24)	7.48 (0.23)
4. CRP > 10 mg/L	12 (13)	8.08 (0.31)

Note. AHA category 1 = low risk; category 2 = average risk; category 3 = high risk (Pearson et al., 2003). The fourth category was based on the Framingham Study (Dhingra et al., 2007), and may indicate acute inflammation. Salivary CRP values were log-transformed.

Adjusted mean levels of salivary CRP.

^**

p < .01